This is a multi-drug oral regimen that can be used in type 2 diabetes, so it is not inherently irrational. But it has important concerns:
-
Four glucose-lowering drug classes are being used, yet glucose is still 345. This indicates treatment failure, missed doses, infection/illness, inadequate dose, dietary factors, or possible need for insulin.
-
Glimepiride can cause hypoglycemia, particularly if meals are skipped, intake is poor, or kidney function is reduced.
-
Dapagliflozin may be useful for heart failure or kidney protection in suitable patients, but can worsen dehydration and rarely cause ketoacidosis. It needs caution during vomiting, fever, fasting, poor fluid intake, acute illness, or surgery.
-
Metformin should be reviewed against kidney function and dehydration status. Its appropriateness cannot be confirmed without creatinine/eGFR.
-
The bill alone does not show the dose timing, HbA1c, fasting/post-meal readings, kidney function, weight loss symptoms, ketones, or infection evaluation. Therefore no one can safely judge the exact regimen or alter it based on this bill alone.
For blood glucose
≥300 mg/dL, current ADA guidance says insulin should be considered, especially if there are hyperglycemic symptoms, weight loss, ketosis, or illness. See the
ADA 2026 pharmacotherapy guidance.